Allergy Therapeutics (LON:AGY) Shares Up 11.1% – What’s Next?

Allergy Therapeutics plc (LON:AGY) shares were up 11.1% during mid-day trading on Thursday . The stock traded as high as GBX 10 and last traded at GBX 10. Approximately 578,138 shares changed hands during trading, an increase of 92% from the average daily volume of 300,673 shares. The stock had previously closed at GBX 9.

Allergy Therapeutics Stock Performance

The company has a current ratio of 1.63, a quick ratio of 1.48 and a debt-to-equity ratio of 835.48. The company has a market cap of £614.14 million, a PE ratio of -11.90, a P/E/G ratio of -30.70 and a beta of 1.40. The firm’s 50-day simple moving average is GBX 11.24 and its two-hundred day simple moving average is GBX 9.52.

Allergy Therapeutics (LON:AGY) last posted its quarterly earnings data on Monday, February 16th. The company reported GBX (0.84) EPS for the quarter. Allergy Therapeutics had a negative return on equity of 266.59% and a negative net margin of 72.86%. As a group, research analysts anticipate that Allergy Therapeutics plc will post -2.56 earnings per share for the current fiscal year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.